Global Oral Proteins and Peptides Market Size By Type (Linaclotide, Plecanatide), By Application (Gastric And Digestive Disorders, Bone Diseases), By Region, And Segment Forecasts, 2023 to 2032

The Global Oral Proteins and Peptides Market was valued at USD 1.1 billion in 2023 and is projected to reach USD 3.4 billion by 2031, expanding at a CAGR of 15.2% during the forecast period from 2023 to 2031. The market is gaining momentum due to the increasing demand for non-invasive drug delivery options, rising prevalence of chronic diseases such as diabetes and cancer, and advancements in oral drug formulation technologies. The ability of oral proteins and peptides to offer targeted, efficient, and patient-friendly therapeutic outcomes positions them as a transformative segment in biopharmaceutical delivery.

Drivers:

1. Rising Demand for Non-Invasive Drug Delivery:

The discomfort associated with injectable drugs has spurred interest in oral alternatives. Oral proteins and peptides offer a more convenient and patient-compliant approach, particularly beneficial for chronic disease patients who require long-term treatment.

2. Advancements in Drug Delivery Technologies:

Innovative formulation technologies such as permeation enhancers, enzyme inhibitors, and nanocarriers are improving the bioavailability of orally administered proteins and peptides, supporting their commercial viability.

3. Growth in Biopharmaceuticals Market:

As biopharmaceuticals continue to dominate the global pharmaceutical landscape, there's a parallel push toward developing oral delivery options for peptide- and protein-based drugs to expand patient accessibility and adherence.

Restraints:

1. Stability and Absorption Challenges:

Proteins and peptides are highly sensitive to degradation in the gastrointestinal tract. Overcoming enzymatic breakdown and ensuring effective absorption remain key barriers to wider market adoption.

2. High R&D and Manufacturing Costs:

Developing oral protein and peptide drugs requires complex technologies and rigorous clinical testing, resulting in higher costs and longer time-to-market compared to conventional therapies.

Opportunity:

1. Expansion in Emerging Markets:

Emerging economies are witnessing an increase in healthcare expenditure and chronic disease prevalence, creating fertile ground for the adoption of advanced drug delivery solutions like oral peptides.

2. Strong Pipeline and Strategic Collaborations:

An increasing number of pharmaceutical companies are investing in the development of oral protein-based drugs, and strategic partnerships between biotech firms and drug delivery companies are accelerating innovation in this space.

Market by System Type Insights:

The Oral Peptide Drug Delivery Systems segment dominated in 2023, accounting for the highest market share. This includes systems utilizing permeation enhancers and enzyme inhibitors. These systems are gaining popularity for their ability to improve gastrointestinal absorption without compromising protein structure.

Market by End-use Insights:

The Diabetes Management segment emerged as the leading end-use category in 2023. Oral insulin formulations and GLP-1 receptor agonists are in high demand due to the global diabetes epidemic. Cancer therapy and hormonal disorders are also expected to register significant growth in the forecast period.

Market by Regional Insights:

North America held the largest market share in 2023, driven by robust R&D infrastructure, high healthcare expenditure, and early adoption of novel therapies. However, Asia-Pacific is anticipated to witness the fastest CAGR during the forecast period due to a large patient population, increasing chronic disease incidence, and growing pharmaceutical investments in the region.

Competitive Scenario:

Key players in the Global Oral Proteins and Peptides Market include Novo Nordisk A/S, Oramed Pharmaceuticals Inc., Biocon Limited, Enteris BioPharma, Chiasma Inc., Rani Therapeutics, Ipsen, Emisphere Technologies, and Roche. Companies are focusing on partnerships, acquisitions, and proprietary delivery platforms to enhance market presence.

Key Developments:

In 2023, Oramed Pharmaceuticals advanced its Phase III clinical trials for oral insulin, marking a milestone in non-invasive diabetes treatment.

Rani Therapeutics announced the successful trial of its RaniPill platform in delivering biologics orally, expected to reshape drug delivery for chronic conditions.

Novo Nordisk expanded its oral semaglutide portfolio, targeting new therapeutic indications beyond diabetes.

Scope of Work – Global Oral Proteins and Peptides Market

FAQs:

1) What is the current market size of the Global Oral Proteins and Peptides Market?

The market size was valued at USD 1.1 billion in 2023.

2) What is the major growth driver of the Global Oral Proteins and Peptides Market?

The primary growth driver is the rising demand for non-invasive, patient-friendly drug delivery methods.

3) Which is the larg